This revision updates and clarifies the 1987. Manufacturing of aseptic products is performed in the ‘aseptic’ processing area, which prevents contamination by excluding microorganisms during processing. Personnel performing environmental monitoring (em) in sterile product facilities shall be trained and qualified to work in classified areas, including aseptic processing areas,.
Lil’ Kim & JayZ (2000) Lil' Kim UK
Monitoring for critical areas should be continuous and the zone immediately surrounding the product whenever the product or open container is exposed to the environment. This guidance replaces the 1987 industry guideline on sterile drug products produced by aseptic processing (aseptic processing guideline). One of the principal ways to keep contamination under control is to monitor the environment for viable and nonviable particles and ensure that all contamination is within the gmp requirements.
Fda gfi titled insanitary conditions at compounding facilities states, fda has observed the lack of adequate environmental monitoring as an insanitary condition.
According to the usp 797, impaction on media plates is the preferred method for viable. In recent years, the fda response to companies with insufficient proof of control over their production has become more aggressive, demonstrated by the rise in 483s and.
